518 results on '"Vekemans, Johan"'
Search Results
2. Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland
3. Measuring indirect transmission-reducing effects in tuberculosis vaccine efficacy trials: why and how?
4. Efficacy of RTS,S/AS01E malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5–17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial
5. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial
6. A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India
7. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial
8. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
9. HIV immunoprophylaxis: preparing the pathway from proof of concept to policy decision and use
10. What is next for BCG revaccination to prevent tuberculosis?
11. Potential effect of age of BCG vaccination on global paediatric tuberculosis mortality: a modelling study
12. List of Contributors
13. Group A Streptococcus Vaccines
14. Serocorrelates of protection against infant group B streptococcus disease
15. Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland
16. Immune Responses to the RTS,S/AS01 Malaria Vaccine Candidate: Lessons from Human Immunology, Parasitologic and Clinical Evaluations
17. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates
18. Building momentum for malaria vaccine research and development: key considerations
19. An aspiration to radically shorten phase 3 TB vaccine trials
20. Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults.
21. Clinical trials of tuberculosis vaccines in the era of increased access to preventive antibiotic treatment
22. Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial
23. Strain-specific Plasmodium falciparum multifunctional CD4+ T cell cytokine expression in Malian children immunized with the FMP2.1/AS02A vaccine candidate
24. Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study
25. Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01 B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP
26. Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01
27. Contributors
28. Malaria Vaccines
29. The march toward malaria vaccines
30. Development of the RTS,S/AS Vaccine Candidate from Concept to Phase III
31. Efficacy of RTS,S/AS01E malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5–17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial
32. Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP
33. Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine
34. Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)
35. Molecular Basis of Allele-Specific Efficacy of a Blood-Stage Malaria Vaccine: Vaccine Development Implications
36. Tuberculosis vaccines: Rising opportunities
37. Major Global Vaccine Challenges: Recent Progress in Malaria Vaccine Development
38. Contributors
39. Effect of the Pre-erythrocytic Candidate Malaria Vaccine RTS,S/AS01 E on Blood Stage Immunity in Young Children
40. Evaluation of the Safety and Immunogenicity of the RTS,S/AS01 E Malaria Candidate Vaccine When Integrated in the Expanded Program of Immunization
41. Long-Term Safety and Efficacy of the RTS,S/AS02A Malaria Vaccine in Mozambican Children
42. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial
43. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial
44. Delay in Motor Development of Twins in Africa: A Prospective Cohort Study
45. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 VOC 202012/01 (B.1.1.7), an exploratory analysis of a randomised controlled trial
46. HLA-B*35—Restricted CD8 T Cell Epitopes in the Antigen 85 Complex of Mycobacterium tuberculosis
47. Chapter 14 - Group A Streptococcus Vaccines
48. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
49. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
50. Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.